What clinical features would lead you to choose lutetium-177–PSMA radioligand therapy over alternative systemic therapies in mCRPC with osseous metastases?  

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This question is inspired by the Plenary Session Presentation "Safety and Efficacy of Lu-177 PSMA-617 Versus Established Therapies in mCRPC: Pooled Evidence from Randomized Phase II/III Trials" by Dr. Mohammad Arfat Ganiyani